ArticleScientific reports2026
Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational diabetes mellitus (GDM) is among the most common complications during pregnancy. It is characterized by hyperglycemia that is first identified during pregnancy, typically in the second or third trimesters. However, the relatively late diagnosis limits timely glycemic control and preventive interventions. The present study aimed to evaluate the diagnostic potential of serum afamin and fibroblast growth factor 21 (FGF21) as early predictive biomarkers for GDM. The study involved 17 healthy pregnant women and 26 pregnant women with one or more risk factors for developing GDM. Fasting blood samples were collected in the 1st (8-12 weeks) and 2nd (22-28 weeks) trimesters of pregnancy. Higher serum afamin level was observed in GDM group at 1st trimester (92.9 ± 34.51 ng/ml) compared to normal pregnancy (57.1 ± 25.15 ng/ml). At 2nd trimester, no significant difference in circulated serum afamin was noted between the two groups (73.2 ± 20.30 ng/ml and 68.3 ± 18.74 ng/ml, for GDM and normal pregnancy, respectively). The study also indicated higher serum FGF21 in pregnancy complicated with GDM compared to normal pregnancy at both sampling times (1st trimester: 140.8 ± 32.83 and 97.1 ± 21.43 Pg/ml for GDM and normal; 2nd trimester: 123.8 ± 41.85 and 89.4 ± 32.53 Pg/ml for GDM and normal). At 1st trimester no significant correlations were noted between afamin and all parameters in normal pregnancy, however, in pregnancy complicated with GDM, positive correlations were noted between the hormone and the diabetic profile parameters and baby birth weight. At both 1st and 2nd trimesters, no correlation between FGF21 with all tested parameters, either in normal or complicated pregnancies. ROC curve analysis demonstrated that afamin (AUC = 0.826, P < 0.001), FGF21 (AUC = 0.877, P < 0.001), and their combined assessment (AUC = 0.9, P < 0.001) were strong predictors of GDM development at 1st trimester before the development of the disease than expectant mothers with normal pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.